Terms: = Head and neck cancer AND KDR, VEGFR2, 3791, ENSG00000128052, P35968, VEGFR, CD309, FLK1 AND Staging
4 results:
1. Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial.
Zhang G; Yuan J; Pan C; Xu Q; Cui X; Zhang J; Liu M; Song Z; Wu L; Wu D; Luo H; Hu Y; Jiao S; Yang B
EBioMedicine; 2023 Apr; 90():104515. PubMed ID: 36921563
[TBL] [Abstract] [Full Text] [Related]
2. Immunoexpression of vegfr-3, but not the immunoexpression of VEGF-C or lymphatic density, is correlated with metastasis in lower lip squamous cell carcinoma.
de Aquino AR; Nonaka CF; de Carvalho CH; Demeda CF; de Souza LB; Pinto LP
Int J Oral Maxillofac Surg; 2017 Jan; 46(1):16-23. PubMed ID: 27745792
[TBL] [Abstract] [Full Text] [Related]
3. Long-term follow-up of immunocytochemical analysis of vascular endothelial growth factor (VEGF), and its two receptors, VEGF-R1 (Flt-1) and VEGF-R2 (Flk-1/kdr), in oesophagogastric cancer.
Gray RT; O'Donnell ME; Maxwell P; McGuigan JA; Spence GM
Int J Biol Markers; 2013 Apr; 28(1):63-70. PubMed ID: 23250775
[TBL] [Abstract] [Full Text] [Related]
4. Circulating lymphangiogenic growth factors in gastrointestinal solid tumors, could they be of any clinical significance?
Tsirlis TD; Papastratis G; Masselou K; Tsigris C; Papachristodoulou A; Kostakis A; Nikiteas NI
World J Gastroenterol; 2008 May; 14(17):2691-701. PubMed ID: 18461654
[TBL] [Abstract] [Full Text] [Related]
